Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma

被引：0
|
作者：
Parrondo, Ricardo D. [1 ]
Laplant, Betsy R. [2 ]
Elliott, Jamie [1 ]
Fernandez, Andre [1 ]
Flott, Caitlin J. [1 ]
Arrington, Diedre [1 ]
Chapin, Dustin [1 ]
Brown, Jade [1 ]
Das, Saurav [1 ]
Roy, Vivek [1 ]
Chanan-Khan, Asher A. [1 ,3 ]
Ailawadhi, Sikander [1 ,3 ]
机构：
[1] Mayo Clin, Canc Ctr, Dept Hematol Oncol, Jacksonville, FL 32224 USA
[2] Mayo Clin, Quantitat Hlth Sci, Rochester, MN USA
[3] Mayo Clin, Ctr Canc, Dept Canc Biol, Jacksonville, FL 32224 USA
来源：
BLOOD CANCER JOURNAL | 2024年 / 14卷 / 01期
关键词：
D O I：
10.1038/s41408-024-01134-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma
    Amrita Krishnan
    Prashant Kapoor
    Joycelynne M. Palmer
    Ni-Chun Tsai
    Shaji Kumar
    Sagar Lonial
    Myo Htut
    Chatchada Karanes
    Nitya Nathwani
    Michael Rosenzweig
    Firoozeh Sahebi
    George Somlo
    Lupe Duarte
    James F. Sanchez
    Daniel Auclair
    Stephen J. Forman
    Jesus G. Berdeja
    Leukemia, 2018, 32 : 1567 - 1574
  • [22] Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma
    Krishnan, Amrita
    Kapoor, Prashant
    Palmer, Joycelynne M.
    Tsai, Ni-Chun
    Kumar, Shaji
    Lonial, Sagar
    Htut, Myo
    Karanes, Chatchada
    Nathwani, Nitya
    Rosenzweig, Michael
    Sahebi, Firoozeh
    Somlo, George
    Duarte, Lupe
    Sanchez, James F.
    Auclair, Daniel
    Forman, Stephen J.
    Berdeja, Jesus G.
    LEUKEMIA, 2018, 32 (07) : 1567 - 1574
  • [23] A randomized phase 2 study of pomalidomide/dexamethasone with or without elotuzumab in patients with relapsed/refractory multiple myeloma.
    San Miguel, Jesus
    Raab, Marc S.
    Goldschmidt, Hartmut
    Lonial, Sagar
    Richardson, Paul G.
    Shelat, Suresh
    Bleickardt, Eric W.
    Palumbo, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [24] A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma
    Yashar, David
    Spektor, Tanya M.
    Martinez, Daisy
    Ghermezi, Matthew
    Swift, Regina A.
    Eades, Benjamin
    Schwartz, Gary
    Eshaghian, Shahrooz
    Lim, Stephen
    Vescio, Robert
    Berenson, James R.
    LEUKEMIA & LYMPHOMA, 2022, 63 (04) : 975 - 983
  • [25] A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination with Pomalidomide, Carfilzomib and Dexamethasone for High Risk Relapsed/Refractory Multiple Myeloma Patients
    Berenson, James
    Martinez, Daisy
    Spektor, Tanya
    Sanchez, Armando
    Ghermezi, Matthew
    Swift, Regina
    Eades, Benjamin
    Schwartz, Gary
    Eshaghian, Shahrooz
    Lim, Stephen
    Vescio, Robert
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E249 - E250
  • [26] Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone (DIPD) As Salvage Therapy in Early Relapsed/Refractory Multiple Myeloma
    Kumar, Anupama
    Rosenberg, Aaron S.
    Ball, Edward D.
    Larson, Sarah M.
    Sirianni, Lindsey
    Mulroney, Carolyn M.
    Costello, Caitlin L.
    BLOOD, 2023, 142
  • [27] Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial
    Dimopoulos, Meletios A.
    Dytfeld, Dominik
    Grosicki, Sebastian
    Moreau, Philippe
    Takezako, Naoki
    Hori, Mitsuo
    Leleu, Xavier
    LeBlanc, Richard
    Suzuki, Kenshi
    Raab, Marc S.
    Richardson, Paul G.
    McKiver, Mihaela Popa
    Jou, Ying-Ming
    Yao, David
    Das, Prianka
    San-Miguel, Jesus
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (03) : 568 - +
  • [28] Daratumumab with Pomalidomide and Dexamethasone at First Relapse in Relapsed and/or Refractory Multiple Myeloma ( RRMM) Patients
    不详
    BLOOD, 2021, 138
  • [29] Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma
    Pierceall, William E.
    Amatangelo, Michael D.
    Bahlis, Nizar J.
    Siegel, David S.
    Rahman, Adeeb
    Van Oekelen, Oliver
    Neri, Paola
    Young, Mary
    Chung, Weiyuan
    Serbina, Natalya
    Parekh, Samir
    Agarwal, Amit
    Thakurta, Anjan
    CLINICAL CANCER RESEARCH, 2020, 26 (22) : 5895 - 5902
  • [30] Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial
    Trudel, Suzanne
    Mccurdy, Arleigh
    Louzada, Martha L.
    Parkin, Stephen
    White, Darrell
    Chu, Michael P.
    Kotb, Rami
    Mian, Hira
    Othman, Ibraheem
    Su, Jiandong
    Khan, Aniba
    Gul, Engin
    Reece, Donna
    NATURE MEDICINE, 2024, 30 (03) : 543 - 551
12345